Collectively, these studies indicate that TRK inhibitors may offer innovative avenues for CFS treatment by targeting ETV6-NTRK3 activation inhibition. The gene discussed is NTRK1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.